Healthcare [ 3/11 ] | Drug Manufacturers—General [ 54/157 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Jan 31, 23 | 4.09
Decreased by
-6.19%
|
4.10
Decreased by
-0.06%
|
Nov 3, 22 | 4.70
Increased by
+0.64%
|
4.44
Increased by
+1.32%
|
Aug 4, 22 | 4.65
Increased by
+6.16%
|
4.40
Increased by
+1.29%
|
Apr 27, 22 | 4.25
Increased by
+14.86%
|
4.10
Increased by
+0.89%
|
Feb 7, 22 | 4.36
Increased by
+14.44%
|
4.08
Increased by
+1.68%
|
Nov 2, 21 | 4.67
Increased by
+6.86%
|
4.27
Increased by
+2.19%
|
Aug 3, 21 | 4.38
Increased by
+3.06%
|
4.09
Increased by
+1.73%
|
Apr 27, 21 | 3.70
Decreased by
-11.27%
|
4.05
Decreased by
-2.13%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 6.65 B
Decreased by
-0.81%
|
2.14 B
Increased by
+13.75%
|
Increased by
+32.22%
Increased by
+14.67%
|
Jun 30, 22 | 6.59 B
Increased by
+1.04%
|
1.32 B
Increased by
+183.84%
|
Increased by
+19.97%
Increased by
+180.91%
|
Mar 31, 22 | 6.24 B
Increased by
+5.71%
|
1.48 B
Decreased by
-10.33%
|
Increased by
+23.66%
Decreased by
-15.17%
|
Dec 31, 21 | 6.85 B
Increased by
+3.20%
|
1.90 B
Increased by
+17.59%
|
Increased by
+27.74%
Increased by
+13.94%
|
Sep 30, 21 | 6.71 B
Increased by
+4.41%
|
1.88 B
Decreased by
-6.78%
|
Increased by
+28.09%
Decreased by
-10.71%
|
Jun 30, 21 | 6.53 B
Increased by
+5.16%
|
464.00 M
Decreased by
-74.27%
|
Increased by
+7.11%
Decreased by
-75.53%
|
Mar 31, 21 | 5.90 B
Decreased by
-4.22%
|
1.65 B
Decreased by
-9.81%
|
Increased by
+27.89%
Decreased by
-5.83%
|
Dec 31, 20 | 6.63 B
Increased by
+7.05%
|
1.61 B
Decreased by
-5.17%
|
Increased by
+24.34%
Decreased by
-11.41%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.